University of Massachusetts

1. Moderna TX, Inc. $3,193,529 346 payments
2. Pfizer Inc. $3,104,576 244 payments
3. Incyte Corporation $1,269,161 111 payments
4. Genentech, Inc. $1,244,001 162 payments
5. AbbVie, Inc. $666,543 155 payments
6. Janssen Research & Development, LLC $549,159 75 payments
7. Otsuka Pharmaceutical Development & Commercialization, Inc. $516,081 14 payments
8. Rhythm Pharmaceuticals, Inc. $449,653 199 payments
9. Novartis Pharmaceuticals Corporation $440,301 5 payments
10. Merck Sharp & Dohme Corporation $430,413 22 payments

1. A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health $1,341,862 77 payments
2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT) $1,190,827 30 payments
3. A Phase 123 Placebocontrolled Randomized Observerblind Dosefinding Study to Evaluate the Safety Tolerability Immunogenicity and Efficacy of Sarscov2 Rna Vaccine Candidates Against Covid19 in Healthy Adults $887,183 54 payments
4. A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adolescents 12 to <18 years of age $780,892 38 payments
5. A Phase 4 Study Using A Testnegative Design to Evaluate the Effectiveness of A 20Valent Pneumococcal Conjugate Vaccine Against Vaccinetype Radiologicallyconfirmed Communityacquired Pneumonia in Adults 65 Years of Age $711,980 51 payments
6. A Phase 3b, Open-Label, Safety and Immunogenicity Study of SARS CoV 2 mRNA-1273 Vaccine in Adult Solid Organ Transplant Recipients and Healthy Controls $498,497 32 payments
7. A Phase 3 Master Protocol to Evaluate Additional Doses of Bnt162b2 in Healthy Individuals Previously Vaccinated With Bnt162b2 $455,000 30 payments
8. Eclipse $430,240 33 payments
9. A Randomized Doubleblind Phase 3 Study of Avelumab in Combination With Standard of Care Chemoradiotherapy Cisplatin Plus Definitive Radiation Therapy Versus Standard of Care Chemoradiotherapy in the Frontline Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck $426,116 6 payments
10. Ocarina I $424,909 38 payments

1. Patient care $440,644 55 payments
2. Other $140,515 6 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.